Form 13-F position report

HALOZYME THERAPEUTICS INC

Reported by GW&K Investment Management LLC

HALO CUSIP 40637H109 Manager CIK 0001082917

Reported 1,140,057 shares, down 213,826 (15.8%) from the prior quarter.

Reported value 18.8%; share count -15.8% vs. the prior quarter.

Reduced
% of reported 13F value 1.07% This manager · Q3 2026
Shares 1,140,057 Quarter-end amount reported
Reported value $125,863,000 Fair value at quarter end
Consecutive quarters held 24 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 62673000
2022-03-31 65956000
2022-06-30 72309000
2022-09-30 87108000
2022-12-31 118856000
2023-03-31 91736000
2023-06-30 85831000
2023-09-30 89552000
2023-12-31 82293000
2024-03-31 89369000
2024-06-30 114145000
2024-09-30 100872000
2024-12-31 83459000
2025-03-31 93475000
2025-06-30 74104000
2025-09-30 92535000
2025-12-31 84439000
2026-03-31 90086000
2026-06-30 105969000
2026-09-30 125863000

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for HALOZYME THERAPEUTICS INC held by GW&K Investment Management LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 1,140,057 -213,826 (-15.8%) 1.07% $125,863,000 2026-11-10
Q2 2026 Reduced 1,353,883 -39,992 (-2.9%) 0.83% $105,969,000 2026-08-12
Q1 2026 Added 1,393,875 +139,227 (11.1%) 0.79% $90,086,000 2026-05-13
Q4 2025 Reduced 1,254,648 -7,069 (-0.6%) 0.73% $84,439,000 2026-02-11
Q3 2025 Reduced 1,261,717 -162,799 (-11.4%) 0.82% $92,535,000 2025-11-12
Q2 2025 Reduced 1,424,516 -40,375 (-2.8%) 0.66% $74,104,000 2025-08-11
Q1 2025 Reduced 1,464,891 -280,750 (-16.1%) 0.87% $93,475,000 2025-05-05
Q4 2024 Reduced 1,745,641 -16,620 (-0.9%) 0.71% $83,459,000 2025-02-05
Q3 2024 Reduced 1,762,261 -417,744 (-19.2%) 0.86% $100,872,000 2024-11-07
Q2 2024 Reduced 2,180,005 -16,872 (-0.8%) 1.04% $114,145,000 2024-08-12
Q1 2024 Reduced 2,196,877 -29,661 (-1.3%) 0.79% $89,369,000 2024-05-08
Q4 2023 Reduced 2,226,538 -117,767 (-5.0%) 0.77% $82,293,000 2024-02-09
Q3 2023 Reduced 2,344,305 -35,284 (-1.5%) 0.9% $89,552,000 2023-11-09
Q2 2023 Reduced 2,379,589 -22,526 (-0.9%) 0.81% $85,831,000 2023-08-09
Q1 2023 Added 2,402,115 +313,259 (15.0%) 0.89% $91,736,000 2023-05-09
Q4 2022 Reduced 2,088,856 -114,186 (-5.2%) 1.21% $118,856,000 2023-02-10
Q3 2022 Added 2,203,042 +559,654 (34.1%) 0.96% $87,108,000 2022-11-09
Q2 2022 Reduced 1,643,388 -10,471 (-0.6%) 0.78% $72,309,000 2022-08-09
Q1 2022 Added 1,653,859 +95,215 (6.1%) 0.59% $65,956,000 2022-05-09
Q4 2021 Added 1,558,644 +59,875 (4.0%) 0.52% $62,673,000 2022-02-11
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

826 managers reported HALOZYME THERAPEUTICS INC for Q3 2026.

Managers reporting HALOZYME THERAPEUTICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 13,668,566 +397,471 0.02% $1,509,009,584 9 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Reduced 5,106,451 -244,861 0.01% $563,752,190 3 qtrs
STATE STREET CORPORATION Reduced 5,063,578 -115,856 0.02% $559,019,011 54 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Reduced 4,986,956 -312,052 0.02% $550,559,942 3 qtrs
Invesco Ltd Added 3,534,220 +356,223 0.03% $390,177,887 46 qtrs
TWO SIGMA INVESTMENTS LP Added 3,519,157 +1,865,872 0.27% $388,514,933 11 qtrs
D E Shaw & Co Inc Added 3,373,506 +1,367,027 0.18% $372,435,062 41 qtrs
MORGAN STANLEY Added 2,850,713 +18,119 0.02% $314,718,948 54 qtrs
Boston Partners Reduced 2,763,837 -9,731 0.27% $305,123,609 13 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 2,414,434 -105,517 0.01% $266,611,110 54 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 10, 2026
Filing type
13F-HR
Position type
COMMON

Voting authority reported

Sole
1,072,018
Shared
67,611
None
427

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.